Literature DB >> 308354

Clinical significance of antibodies to soluble extractable nuclear antigens (anti-ENA).

A Gaudreau, B Amor, M F Kahn, A Ryckewaert, J Sany, A P Peltier.   

Abstract

Clinical and biological manifestations have been studied in 134 patients whose serum had antibodies to soluble extractable nuclear antigens (ENA). 85 of the patients had anti-RNP antibodies, 18 had anti-Sm antibodies, and 31 had antibodies to one or more soluble nuclear antigen. In all groups, the predominant clinical manifestations were polyarthritis, Raynaud's phenomenon, fever, and skin involvement. Renal disease was less common in those patients with anti-RNP antibodies than in the other patients. Most patients with definite renal disease (13 out of 15) also had circulating anti-DNA antibodies. The final diagnoses in these 134 patients were well defined connective tissue disease in 59; overlap syndromes in 34; a limited clinical syndrome made up of polyarthritis Raynaud's phenomenon--often with swollen fingers--and/or hypergammaglobulin-aemia in 31, and various other clinical conditions in 10.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 308354      PMCID: PMC1000237          DOI: 10.1136/ard.37.4.321

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  22 in total

1.  The L. E. cell and the L. E. serum factors.

Authors:  H R HOLMAN; H R DEICHER; H G KUNKEL
Journal:  Bull N Y Acad Med       Date:  1959-07

2.  Systemic scleroderma, A clinical study of 727 cases.

Authors:  D L TUFFANELLI; R K WINKELMANN
Journal:  Arch Dermatol       Date:  1961-09

3.  [Anti-deoxyribonucleic acid antibodies: comparison of results provided by 3 research methods].

Authors:  M C Osnos; L Cyna; T Haim; A P Peltier; M F Kahn; A Ryckewaert
Journal:  Rev Rhum Mal Osteoartic       Date:  1977-02

4.  Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera.

Authors:  M Mattioli; M Reichlin
Journal:  J Immunol       Date:  1971-11       Impact factor: 5.422

5.  Ribonucleoprotein (RNP) soluble nuclear antigen: demonstration of its reaction with serum antibodies by counter-immunoelectrophoresis and further partial characterization.

Authors:  A P Peltier; C Aussel; T Haim; L Cyna
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

6.  Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).

Authors:  G C Sharp; W S Irvin; E M Tan; R G Gould; H R Holman
Journal:  Am J Med       Date:  1972-02       Impact factor: 4.965

7.  Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases.

Authors:  G C Sharp; W S Irvin; C M May; H R Holman; F C McDuffie; E V Hess; F R Schmid
Journal:  N Engl J Med       Date:  1976-11-18       Impact factor: 91.245

8.  Antinuclear antibody with distinct specificity for polymyositis.

Authors:  J F Wolfe; E Adelstein; G C Sharp
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

9.  Progressive systemic sclerosis (PSS) and localized scleroderma (morphea) with positive LE cell test and unusual systemic manifesstations compatible with systemic lupus erythematous (SLE): presentation of 14 cases including one set of identical twins, one with scleroderma dn the other with SLE. Review of the literature.

Authors:  E L Dubois; S Chandor; G J Friou; M Bischel
Journal:  Medicine (Baltimore)       Date:  1971-05       Impact factor: 1.889

10.  A soluble acidic protein of the cell nucleus which reacts with serum from patients with systemic lupus erythermatosus and Sjögren's syndrome.

Authors:  M Akizuki; R Powers; H R Holman
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

View more
  11 in total

1.  MCTD: is it rare in India?

Authors:  A Lawrence; A Aggarwal; R Misra
Journal:  Clin Rheumatol       Date:  2006-04-06       Impact factor: 2.980

2.  Mixed connective tissue disease with associated glomerulonephritis and hypocomplementaemia.

Authors:  T G Palferman; C S McIntosh; M Kershaw
Journal:  Postgrad Med J       Date:  1980-03       Impact factor: 2.401

3.  Antibodies to distinct polypeptides of RNA polymerase I in sera from patients with rheumatic autoimmune disease.

Authors:  D A Stetler; K M Rose; M E Wenger; C M Berlin; S T Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

4.  A common idiotype expressed on a murine anti-Sm monoclonal antibody and antibodies in SLE sera.

Authors:  M Takei; H Dang; N Talal
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

5.  Clinical profiles of patients with antibodies to nuclear ribonucleoprotein.

Authors:  J Calderon; V Rodriguez-Valverde; S Sanchez Andrade; J L Riestra; J Gomez-Reyno
Journal:  Clin Rheumatol       Date:  1984-12       Impact factor: 2.980

6.  Systemic lupus erythematosus: clinical manifestations and immunological parameters in 194 patients. Subgroup classification of SLE.

Authors:  J Antolin; M J Amerigo; A Cantabrana; A Roces; P Jimenez
Journal:  Clin Rheumatol       Date:  1995-11       Impact factor: 2.980

7.  Antigen specificity of antihistone antibodies in connective tissue disease patients with anti-U1RNP antibodies.

Authors:  Takamasa Wayaku; Minoru Hasegawa; Kenzo Kaji; Miki Kondo; Yuki Saito; Hidemitsu Orito; Mayuka Horikawa; Takashi Matsushita; Kazuhiro Komura; Ikuko Hayakawa; Yasuhito Hamaguchi; Fumihide Ogawa; Manabu Fujimoto; Kazuhiko Takehara; Shinichi Sato
Journal:  Rheumatol Int       Date:  2007-07-13       Impact factor: 2.631

8.  Is MCTD a distinct entity? Comparison of clinical and laboratory findings in MCTD, SLE, PSS, and RA patients.

Authors:  L S De Clerck; K A Meijers; A Cats
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

9.  Follow-up of 151 patients with high-titer U1RNP antibodies.

Authors:  P B Frandsen; N J Kriegbaum; S Ullman; M Høier-Madsen; A Wiik; P Halberg
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

10.  Analysis of speckled fluorescent antinuclear antibody test antisera using electrofocused nuclear antigens.

Authors:  T B Okarma; J A Krueger; H R Holman
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.